Guest Editors
Dr. Akriti Gupta Jain
Email: jaina9@ccf.org
Affiliation: Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland, United States
Homepage:
Research Interests: internal medicine, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes, myelodysplastic myeloproliferative
Summary
Myeloproliferative neoplasms (MPNs), both Philadelphia positive and negative, including essential thrombocythemia, polycythemia vera, myelofibrosis, and chronic myeloid leukemia, are driven by well-defined genetic lesions yet display marked biological and clinical heterogeneity. While advances in molecular biology have clarified key oncogenic drivers and signaling pathways, translating these insights into durable, disease-modifying therapies remains an ongoing challenge. This is especially true for CML, wherein the discovery of the Philadelphia chromosome and discovery of tyrosine kinase inhibitors transformed the management and, in turn, survival of patients with CML. The discovery of JAK2 mutation and JAK inhibitors has improved management and survival of patients with Philadelphia negative MPNs, but has not transformed care like in CML.
This Special Issue will highlight integrative research spanning MPN pathophysiology, molecular and cellular mechanisms, and translational strategies with direct clinical relevance. By bringing together basic, translational, and clinically oriented investigations, this issue aims to foster a cohesive framework for understanding MPN biology and accelerating the development of more effective, personalized therapeutic approaches.
Keywords
myeloproliferative neoplasms, myelofibrosis, chronic myeloid leukemia, targeted therapy
Login
Register
Submit a Paper
Propose a Special lssue